Opinion|Videos|October 21, 2024
HER2- Mutation Testing Considerations and Timing
Key Takeaways
- Integrating HER2-directed therapies into NSCLC decision-making requires adapting protocols and ensuring timely updates as new therapies emerge.
- Streamlined processes and enhanced communication among multidisciplinary teams are crucial for incorporating new data and therapies.
Panelists discuss how integrating HER2-directed therapies into existing NSCLC decision-making processes presents challenges, focusing on strategies for timely updates as new therapies emerge and the practicalities of HER2- mutation testing, including turnaround times and result interpretation for therapy selection.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- (Kim) What are the key challenges in integrating HER2-directed therapies into existing internal decision-making processes for NSCLC?
- (Heymach) What strategies can be employed to ensure timely updates to internal decision-making processes as new HER2-directed therapies emerge?
- (Iams) What is the typical turnaround time for HER2- mutation testing, and how easy is it to interpret the results received in order to make a therapy selection?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Special Report: The Oncology Care Model, 10 Years Later
2
FDA Approves Tocilizumab-bavi for CAR-T-Induced CRS, Pediatric COVID-19
3
AI Model Challenges Genomic Classifiers in Early Breast Cancer Risk Stratification: Nancy Lin, MD
4
Weight Loss Drugs Can Improve Outcomes in Patients With Heart Failure and Obesity: Sandra Chaparro, MD
5